TAXOTERE 20 mg/1 ml concentrate for solution for infusion clinical trials

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This study is testing a new combination of medicines, Sitravatinib and Nivolumab, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It's for people whose cancer has grown after previous chemotherapy and immunotherapy.